GPhA rebrands to become AAM

15 February 2017
biosimilars_samples_large

The Generic Pharmaceutical Association (GPhA), the USA’s largest trade group representing generic pharmaceutical and biosimilar companies, has rebranded itself as the Association for Accessible Medicines (AAM).

This rebrand has been launched to coincide with the group’s new national campaign to contain the cost of prescription medicines and to spread the word about it.

"Our evolution to AAM reflects an industry-wide recognition that it is time to amplify the critical cost savings and access that generics and biosimilars make possible"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biosimilars